Affimed N.V.
News
Affimed to Present at the Cantor Global Healthcare Conference 2024
Globe Newswire MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) ( Affimed , or the Company ), a clinical-stage immuno-oncology company committed to giving patients back their...\n more…
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Globe Newswire AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable patients: 1 complete response (CR), 3 partial...\n more…
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Globe Newswire MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) ( Affimed or the Company ), a clinical-stage immuno-oncology company committed to giving patients back their...\n more…
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Globe Newswire MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer...\n more…
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nAFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the first quarter of...\n more…
Affimed Reports First Quarter 2024 Financial Results & Business Update
Globe Newswire - Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2...\n more…